The toxicity of N-methylated Sample Clauses

The toxicity of N-methylated βCs The toxicity of the N-methylated βCs has been studied extensively (Xxxxxxx et al. 1989, Xxxxxxxxx et al. 1998, Xxxxxx et al. 2004, Xxxxxx et al. 2006, Xxxxxxxx et al. 2006, Xxxxxxxx et al. 2007). While 2N-methylation has been shown to confer toxic properties and dopaminergic neuron specificity to most βCs, 9N-methylation of 2- MeNH appears to be a crucial step in toxicity potentiation as 2,9-diMeNH has been shown to be markedly more toxic than 2-MeNH in Neuro 2A cells (Bonnet et al. 2004), DAT-transfected and wild type human embryonic kidney (HEK) cells (Xxxxxxxx et al. 2007) and primary dopaminergic neurons (Xxxxxx et al. 2006). In fact, 2,9-diMeNH has shown comparable toxicity to MPP+ with a reduced reliance on DAT (Xxxxxx et al. 2004, Xxxxxx et al. 2006, Xxxxxxxx et al. 2007). Despite a lowered DAT dependency relative to MPP+, 2,9-diMeNH has been shown to be selective for dopaminergic neurons compared with other neurons and non- neuronal cells (Xxxxxxxx et al. 2006). N-methylated βCs, like MPP+, are principally thought to act via inhibition of CxI of the mitochondrial respiratory chain, although weaker inhibition at complexes II and III have also been reported (Albores et al. 1990, Xxxxxxx et al. 1992, Xxxxxx et al.
AutoNDA by SimpleDocs

Related to The toxicity of N-methylated

  • Prohibition Against Selecting and Installing Products Containing Hazardous Materials The Contractor shall not select, install or otherwise incorporate any products or materials containing Hazardous Materials within the boundaries of the Site. Should the Contractor or any Subcontractors have knowledge that, or believe that, an item, component, material, substance, or accessory within a product or assembly selected by the Contractor or any Subcontractor may contain Hazardous Materials it is the Contractor’s responsibility to secure a written certification from the manufacturer of any suspected material which identifies the specific Hazardous Material(s) contained, together with the Material Safety Data Sheets (MSDS) for such materials which shall be submitted to the Owner and Design Professional.

  • Biological Samples If so specified in the Protocol, Institution and Principal Investigator may collect and provide to Sponsor or its designee Biological Samples (“Biological Samples”). 12.2.

  • Dangerous Goods, Special Wastes, Pesticides and Harmful Substances Where employees are required to work with or are exposed to any dangerous good, special waste, pesticide or harmful substance, the Employer shall ensure that the employees are adequately trained in the identification, safe handling, use, storage, and/or disposal of same.

  • Musculoskeletal Injury Prevention and Control (a) The Hospital in consultation with the Joint Health and Safety Committee (JHSC) shall develop, establish and put into effect, musculoskeletal prevention and control measures, procedures, practices and training for the health and safety of employees.

  • Hepatitis B Vaccine Where the Hospital identifies high risk areas where employees are exposed to Hepatitis B, the Hospital will provide, at no cost to the employees, a Hepatitis B vaccine.

  • Vaccination and Inoculation (a) The Employer agrees to take all reasonable precautions, including in-service seminars, to limit the spread of infectious diseases among employees.

  • Infectious Diseases The Employer and the Union desire to arrest the spread of infectious diseases in the nursing home. To achieve this objective, the Joint Health and Safety Committee may review and offer input into infection control programs and protocols including surveillance, outbreak control, isolation, precautions, worker education and training, and personal protective equipment. The Employer will provide training and ongoing education in communicable disease recognition, use of personal protective equipment, decontamination of equipment, and disposal of hazardous waste.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Smoke Free Environment The Lessor shall make all parts of the leased premise smoke-free. "

  • Infectious Disease Where an employee produces documentary evidence that:

Time is Money Join Law Insider Premium to draft better contracts faster.